Drug Trial Radar · NCT03733444
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
Last checked: Nov 19, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
781
Actual
Start
Nov 5, 2018
Primary completion
Mar 30, 2021
Study completion Mar 30, 2021
Sponsor
- Lead sponsor
- Lakefront Biotherapeutics NVIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690Drug
GLPG1690, film-coated tablets for oral use.
PlaceboDrug
Matching placebo, film-coated tablets for oral use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Rate of Decline in Forced Vital Capacity (FVC) up to Week 52Time frame: Baseline up to week 52
Locations
132 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Pulmonary Specialists
Phoenix, Arizona
University of Arizona College of Medicine
Tucson, Arizona
Keck School of Medicine of USC
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
University of California, San Francisco Medical Center
San Francisco, California
St. Francis Medical Institute
Clearwater, Florida
University of Miami
Miami, Florida
Renstar Medical Research
Ocala, Florida
Central Florida Pulmonary Group PA
Orlando, Florida
Piedmont Healthcare
Atlanta, Georgia
Emory University
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Brigham and Womens Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
University of Michigan Health System (UMHS)
Ann Arbor, Michigan
Spectrum Health Medical Group
Grand Rapids, Michigan
University of Minnesota Medical Center
Minneapolis, Minnesota
Cardio Pulmonary Associates
Chesterfield, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Atlantic Respiratory Institute
Summit, New Jersey
Lovelace Scientific Resources Inc
Albuquerque, New Mexico
Albany Medical Center
Albany, New York
Columbia University Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Ohio State University
Columbus, Ohio
Mercy Health - St. Vincent Medical Center
Toledo, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Temple Lung Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina - PPDS
Charleston, South Carolina
University of Vermont
Burlington, Vermont
Inova Fairfax Hospital
Falls Church, Virginia
Centro Médico Dra de Salvo
Buenos Aires, Argentina
Hospital Privado Centro Médico de Córdoba
Córdoba, Argentina
CEMER Centro Médico de Enfermedades Respiratorias
Florida, Argentina
Hospital Zonal Especializado de Agudos y Crónicos Dr. Antonio A. Cetrangolo
Luján, Argentina
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.